EP0850238A1 - Banque combinatoire de 1,4-benzodiazepine-2,5-diones - Google Patents

Banque combinatoire de 1,4-benzodiazepine-2,5-diones

Info

Publication number
EP0850238A1
EP0850238A1 EP96923532A EP96923532A EP0850238A1 EP 0850238 A1 EP0850238 A1 EP 0850238A1 EP 96923532 A EP96923532 A EP 96923532A EP 96923532 A EP96923532 A EP 96923532A EP 0850238 A1 EP0850238 A1 EP 0850238A1
Authority
EP
European Patent Office
Prior art keywords
resin
formula
linked
aminoacids
azidobenzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96923532A
Other languages
German (de)
English (en)
Other versions
EP0850238A4 (fr
Inventor
Michael H. J. Ohlmeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacopeia LLC
Original Assignee
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Inc filed Critical Pharmacopeia Inc
Publication of EP0850238A1 publication Critical patent/EP0850238A1/fr
Publication of EP0850238A4 publication Critical patent/EP0850238A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms

Definitions

  • the present invention relates to a method of synthesizing a combinatorial library of 1 ,4-benzodiazepin-5-ones on solid supports via an aza-Wittig ring closure, said compounds optionally encoded with tags, and to the use of this library in assays to discover biologically active compounds, and, optionally, to cleave l,4-benzodiazepin-2,5- diones therefrom.
  • R 1 is H, lower alkyl, c-lower alkyl, -or (CH2) R 4 , or R 1 and R 2 , together with the atoms to which they are attached, join to form a 5-, or 6-membered heterocyclic ring, optionally monosubstituted with OH, alkoxy, or arylalkoxy;
  • R 2 is H, loweralkyl, arylR 6 R 7 R8, or heteroarylR 6 R 7 R8, or R 1 and R 2 , together with the atoms to which they are attached, join to form a 5- or 6-membered heterocyclic ring, optionally monosubstituted with OH, alkoxy, or arylalkoxy;
  • R 3 is H or loweralkyl;
  • R 4 is aryl, substituted aryl, heteroaryl, substituted heteroaryl,
  • R5 is H, lower alkyl, -CNHR3R3, or -C(0)R3;
  • R 6 , R 7 , and R 8 is each, independently, H, lower alkyl, lower alkoxy, halogen, aryl, lower alkylthio, X-aryl, X-substituted aryl, lower alkylaryl, C(hal)3, -(CH2) m NR3R5, or -X-CH(C ⁇ 2R 3 )2, or R6 and R 7 , together with the atoms to which they are attached, join to form a 5- or 6-membered heterocyclic ring; and X is O or S.
  • the ligands of Formula II may be detached by photolytic, oxidative, acidic, basic, or other cleavage techniques.
  • acidic cleavage may be represented by:
  • An embodiment of the invention is the solid phase synthesis of l,4-benzodiazepin-2,5-diones via aza-Wittig ring closure.
  • the process comprises: a) attaching a set of suitably protected oc-aminoacids or N- alkyl- ⁇ -aminoacids to solid supports to form resin linked N-alkyl- ⁇ - aminoacids; or b) attaching a set of suitably protected N-unsubstitued- ⁇ - aminoacids to solid supports to form resin linked N-unsubstitued- ⁇ - aminoacids and reductively alkylating said resin linked aminoacids with a set of aldehydes to form resin linked N-arylalkyl or heteroarylalkyl- ⁇ -aminoacids; c) acylating the resin linked N-alkyl- ⁇ -aminoacids or the N-arylalkyl or heteroarylalkyl- ⁇ -a
  • a preferred embodiment of the invention is the solid phase synthesis of l,4-benzodiazepin-2,5-diones via aza-Wittig ring closure, wherein the process comprises: a) reacting a set of suitably protected ⁇ -aminoacids of the formula:
  • step (b) reacting the resin linked aminoacids of step (a), suspended in DMF and acetic acid, with a set of aldehydes of the formula HC(0)R 2 in HOAc/DMF and sodium cyanoborohydride in THF to form resin linked N-alkyl- ⁇ -aminoacids of the formula:
  • step (c) treating the resin linked N-(2-azidobenzoyl)amino esters of step (c), suspended in an involatile solvent (i.e., a non-protic, organic solvent with a boiling point of 80-140 C) such as toluene, xylene, or chlorobenzene, with an excess of a trivalent phosphorus reagent such as triphenylphosphine or tributylphosphine at 80-150°C and then cooling said mixture to room temperature to form resin linked benzodiazepines of formula:
  • an involatile solvent i.e., a non-protic, organic solvent with a boiling point of 80-140 C
  • a trivalent phosphorus reagent such as triphenylphosphine or tributylphosphine at 80-150°C
  • step (d) suspending the resin linked benzodiazepines of step (d) in TF A/water at room temperature for 1-24 hours to form 1,4- benzodiazepin-2,5-diones of formula:
  • a second preferred embodiment of the invention is the solid phase synthesis of l,4-benzodiazepin-2,5-diones and l,3-cyclo-l,4- benzodiazepin-2,5-diones via aza-Wittig ring closure, wherein the process comprises: a) reacting a set of suitably protected ⁇ -aminoacids of the formula:
  • step (b) reacting the resin linked N-alkyl- ⁇ -aminoacids of step (b), in methylene chloride and diisopropylethylamine, with 2- azidobenzoyl chlorides of formula: to form resin linked N-(2-azidobenzoyl)amino esters of formula:
  • step (b) treating the resin linked N-(2-azidobenzoyl)amino esters of step (b), suspended in an involatile solvent (i.e., a non-protic, organic solvent with a boiling point of 80-140 C) such as toluene, xylene, or chlorobenzene, with an excess of a trivalent phosphorus reagent such as triphenylphosphine or tributylphosphine at 80-150°C and then cooling said mixture to room temperature to form resin linked benzodiazepines of formula:
  • an involatile solvent i.e., a non-protic, organic solvent with a boiling point of 80-140 C
  • a trivalent phosphorus reagent such as triphenylphosphine or tributylphosphine at 80-150°C
  • step (c) suspending the resin linked benzodiazepines of step (c) in TF A/water at room temperature for 1-24 hours to form 1,4- benzodiaze ⁇ in-2,5-diones of formula:
  • an aspect of the invention is a method of identifying a compound having a desired characteristic which comprises synthesizing a combinatorial library of Formula I and testing the library of Formula I, either attached to the solid support or detached therefrom, in an assay which identifies compounds of Formula II having the desired characteristic.
  • Another embodiment of the invention is a method of identifying a compound having a desired characteristic which comprises testing the library of Formula I, either attached to the solid support or detached therefrom, in an assay which identifies compounds of Formula II having the desired characteristic.
  • a further embodiment of the invention is determining the structure of any compound so identified.
  • the determination of the structures of compounds having the desired characteristic can be accomplished by decoding the tags (represented by T'-L- in Formula I) or, alternatively, by deconvolution of the library (Smith et al., BioMed. Chem. Lett., 4, 2821 (1994); Kurth et aL, . Org. Chem., 59, 5862 (1994); Murphy et ah, J. Am. Chem. Soc, 111, 7029 (1995); Cambell et aL, J. Am. Chem. Soc, 111, 5381 (1995); and Erb et aL, Proc Nat. Acad. Sci. USA, 91, 11422 (1994)).
  • Another embodiment of the invention is the use of divinylbenzene-cross-linked, polyethyleneglycol-grafted polystyrene beads optionally functionalized with amino groups (for example, TentaGel® S NH2, Rapp Polymere) as the solid supports for constructing a combinatorial library of Formula I or I'.
  • amino groups for example, TentaGel® S NH2, Rapp Polymere
  • Alkyl is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof.
  • “Lower alkyl” means alkyl groups of from 1 to 8 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t- butyl, pentyl, hexyl, octyl, cyclopropylethyl, and the like.
  • “Lower cycloalkyl” includes cycloalkyl groups of from 3 to 8 carbon atoms. Examples of lower cycloalkyl groups include c-propyl, c-butyl, c- pentyl, 2-methylcyclopropyl, cyclopropylmethyl, norbornyl, and the like.
  • Alkenyl is C2-C8 alkenyl of a linear, branched, or cyclic (C5-C6) configuration and combinations thereof.
  • alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, c-hexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.
  • Alkynyl is C2-C8 alkynyl of a linear or branched configuration and combinations thereof.
  • alkenyl groups examples include ethyne, propyne, butyne, pentyne, 3-methyl-l-butyne, 3,3- dimethyl-1-butyne, and the like.
  • Alkoxy means alkoxy groups of from 1 to 8 carbon atoms of a straight, branched, or cyclic configuration and combinations thereof. Examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like.
  • Acylamino means acylamino groups of from 1 to 8 carbon atoms of a straight, branched or cyclic configuration and combinations thereof. Examples of acylamino groups are acetylamino, butylamino, cyclohexylamino, and the like.
  • Hal means halogen, which includes F, Cl, Br, and I.
  • Halophenyl means phenyl substituted by 1-5 halogen atoms. Halophenyl includes pentachlorophenyl, pentafluorophenyl, and 2 ,4,6-trichlorophenyl.
  • the aromatic 6- to 14-membered carbocyclic rings include benzene, naphthalene, indane, tetralin, and fluorene and the 5- to 10- membered aromatic heterocyclic rings include imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole, and pyrazole.
  • Substituted alkyl, alkenyl, or alkynyl means alkyl, alkenyl, or alkynyl wherein up to three H atoms on each C therein are replaced by halogen, hydroxy, loweralkoxy, carboxy, carboalkoxy, carboxamido, cyano, carbonyl, NO2, NR 3 R3, alkylthio, sulfoxide, sulfone, acylamino, amidino, phenyl, benzyl, heteroaryl, phenoxy, benzyloxy, heteroaryloxy, and substituted phenyl, benzyl, heteroaryl, phenoxy, benzyloxy, and heteroaryloxy.
  • the linkers may be any component capable of being selectively cleaved to release both T and II from the solid support. See, e.g., Greene and Wuts, "Protective Groups in Organic Synthesis", 2nd ed., Wiley, 1991.
  • the left-hand bond is the point of attachment to the solid support (via -C(O)- for L' and -C(O)- or -CH2C(0)- for L) and the right-hand bond is the point of attachment to either T or II.
  • the tags of this invention, T are chemical entities which possess several properties: they must be detachable from the solid supports, preferably by photolysis or oxidation; they must be individually differentiable, and preferably separable; they must be stable under the synthetic conditions; they must be capable of being detected at very low concentrations, e.g., IO -18 to IO -9 mole; they should be identifiable with readily-available equipment which does not require sophisticated technical capabilities to operate; and they should be relatively economical.
  • the tags may be structurally related or unrelated, e.g., a homologous series, repetitive functional groups, related members of the Periodic Chart, different isotopes, combinations thereof, and the like.
  • each solid support there will usually be attached at least 0.01 femtomol, usually 0.001-50 pmol, of each tag.
  • the tags may be aliphatic, alicyclic, aromatic, heterocyclic, or combinations thereof.
  • Distinguishing features may be the number of repetitive units, such as methylene groups in an alkyl moiety; alkyleneoxy groups in a polyalkyleneoxy moiety; halo groups in a polyhalo compound; ⁇ - and/or ⁇ -substituted ethylene groups where the substituents may be alkyl groups, oxy, carboxy, amino, halo, or the like; isotopes; etc.
  • the materials upon which the combinatorial syntheses of the invention are performed are referred to as solid supports, beads, and resins.
  • beads, pellets, disks, fibers, gels, or particles such as cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene and optionally grafted with polyethylene glycol and optionally functionalized with amino, hydroxy, carboxy, or halo groups, grafted co-poly beads, poly-acrylamide beads, latex beads, dimethylacrylamide beads optionally cross-linked with N,N'-bis-acryloyl ethylene diamine, glass particles coated with hydrophobic polymer, etc., i.e., material having a rigid or semi-rigid surface; b) soluble supports such as low molecular weight non- cross-linked polystyrene; and.
  • Suitable aminoacid protecting groups are well known in the art and include Fmoc, Alloc (allyloxycarbonyl), etc.
  • R H or lower alkyl
  • B O or NH
  • Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisometric forms which may be defined in terms of absolute stereochemistry as (R) or (S), or as (D) or (L) for amino acids.
  • the present invention is meant to include all such possible diastereomers as well as their racemic and optically pure forms.
  • Optically active (R) and (S), or (D and L), isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
  • the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended to include both E and Z geometric isomers. Likewise, all tautomeric forms are intended to be included.
  • the library of the present invention is useful as a screening tool for discovering new lead structures by evaluation across an array of biological assays, including the discovery of selective inhibition patterns across isozymes.
  • the library is thus a tool for drug discovery; i.e., as a means to discover novel lead compounds by screening the library against a variety of biological targets and to develop structure- activity relationships (SAR) in large families of related compounds.
  • the library may be tested with the ligands attached to the solid supports as depicted in Formula I or I', or the compounds II may be detached prior to evaluation. With the compounds of Formula I or I', screening assays such as FACS sorting and cell lawn assays may be used.
  • tags attached to solid support associated with bioactivity may then be decoded to reveal the structural or synthetic history of the active compound (Ohlmeyer et al., Proc. Natl. Aca ⁇ Sci. USA, 90, 10922-10926, Dec. 1993 and Still et al., Complex Combinatorial Chemical Libraries Encoded with Tags, WO 94/08051) or, alternatively, the structures may be determined by deconvolution.
  • the compounds of the present invention can be prepared according to the following methods.
  • each solid support upon which a compound is being synthesized may be uniquely tagged to define the particular chemical event(s) occurring during that step.
  • the tagging is accomplished using identifiers such as those of Formula IV, which record the sequential events to which the support is exposed during the synthesis, thus providing a reaction history for the compound produced on each support.
  • the identifiers are used in combination with one another to form a binary or higher order encoding scheme permitting a relatively small number of identifiers to encode a relatively large number of reaction products. For example, when used in a binary code, N identifiers can encode up to 2N different compounds and/or conditions.
  • each variable or combination of variables at each step of the synthesis By associating each variable or combination of variables at each step of the synthesis with a combination of identifiers which uniquely define the chosen variables such as reactant, reagent, reaction conditions, or combinations of these, one can use the identifiers to define the reaction history of each solid support.
  • identifiers By associating each variable or combination of variables at each step of the synthesis with a combination of identifiers which uniquely define the chosen variables such as reactant, reagent, reaction conditions, or combinations of these, one can use the identifiers to define the reaction history of each solid support.
  • the syntheses one begins with at least IO 4 , desirably at least IO 7 , and generally not exceeding IO 15 solid supports.
  • IO 15 IO 15 solid supports.
  • the supports Depending on the pre-determined number of choices for the first step, one divides the supports accordingly into as many containers.
  • the appropriate reagents and reaction conditions are applied to each container and the combination of identifier
  • the tagging may be done prior to, concomitantly with, or after the reactions which comprise each choice.
  • sample supports may be picked at any stage and a portion of their tags detached and decoded to verify that the correct tags are bound to the sample supports.
  • one may wash the beads free of any excess reagents or by ⁇ products before proceeding.
  • the supports are combined, mixed, and again divided, this time into as many containers as pre-determined for the number of choices for the second step in the synthesis. This procedure of dividing, reacting, tagging, and remixing is repeated until the combinatorial synthesis is completed.
  • A is suspended in an aprotic, polar solvent such methylene chloride, DMF,
  • the resin is filtered and washed and then suspended in an involatile solvent (i.e., a non-protic, organic solvent with a boiling point of 80-140 C) such as toluene, xylene, or chlorobenzene and treated with an excess of a trivalent phosphorus reagent such as triphenylphosphine or tributylphosphine.
  • an involatile solvent i.e., a non-protic, organic solvent with a boiling point of 80-140 C
  • a trivalent phosphorus reagent such as triphenylphosphine or tributylphosphine.
  • Compounds 4, 8, 11, and 16 have been synthesized by the aza-Wittig method of the present invention.
  • Compound 4 is a known intermediate useful in the synthesis of antitumor antibiotics (Kaneko et aL, Tet. Lett., 1983, p. 5165; Kaneko et al., J. Med. Chem., 1985, p. 388).
  • Compound 8 is a novel compound useful as an intermediate in the synthesis of the antibiotic 5-thioabbeymycin (Kamal et aL, Bioorg. Med. Chem. Lett., 3, p. 743, 1993) and abbeymycin.
  • Compound 11 is a novel compound useful as an intermediate in the synthesis of antitumor antibiotics (Hurley et al., Chem. Res. Toxicol, 1, p. 258, 1988.
  • Compound 16 is a natural product isolated from Penicillium cyclopium with potential antibiotic properties (Framm et al., Eur. J. Biochem, 37, p. 78, 1973.)
  • Resin-linked ⁇ -amino ester, A is suspended in an aprotic, polar solvent such methylene chloride, DMF, THF or ethyl acetate.
  • An excess (2-50 equivalents) of a soluble organic base such as triethylamine, N,N-diisopropylethylamine, or pyridine is added to the suspended resin.
  • an acylation catalyst such as 4- dimethylaminopyridine may be added. This mixture is treated with an excess (2-10 equivalents) of an appropriately substituted 2-azidobenzoyl chloride and agitated at room temperature for 2-24 hr.
  • Resin linked N-(2-azidobenzoyl)ami ⁇ o ester, B is suspended in an involatile solvent such as toluene, xylene, or chlorobenzene and treated with an excess (2-10 equivalents) of a trivalent phosphorus reagent such as triphenylphosphine or tributylphosphine.
  • Resin-linked 1,4- benzodiazepin-5-one, C is suspended in an acidic solution such as trifluoroacetic acid/methylene chloride (50-90% TFA/CH2C12) or hydrogen chloride/dioxane (1-4M HCl/dioxane) and agitated at room temperature for 1-24 hr.
  • an acidic solution such as trifluoroacetic acid/methylene chloride (50-90% TFA/CH2C12) or hydrogen chloride/dioxane (1-4M HCl/dioxane)
  • the resin is filtered and washed with appropriate solvents such as methylene chloride or dioxane.
  • appropriate solvents such as methylene chloride or dioxane.
  • the filtrate and washings are combined and evaporated to give the crude l,4-benzodiazepin-2,5-dione, D, which may be purified and characterized by standard techniques.
  • a) Methyl vanillate (0.729 g, 4.0 mmole), l-hydroxy-9- (2,3,4,5,6-pentachlorophenoxy)nonane (1.634 g, 4.0 mmole) and triphenylphosphine (1,258 g, 4.8 mmole) were dissolved in 20 mL dry toluene under argon.
  • the diazoketone (0.85 g, 1.4 mmole, 82% yield over three steps) was obtained as a pale yellow solid.
  • purification by flash chromatography was no longer necessary, which in some cases had resulted in significant acid-catalyzed decomposition of the identifier.
  • Example 5 the 12 identifiers were used to encode the combinatorial library.
  • N-Fmoc-c ⁇ -4-benzoyloxy-L-proline p-alkoxybenzyl resin was prepared by routine methods as outlined below.
  • TentaGel resin may be modified with bis-Fmoc lysine to increase the available reaction sites for ligand attachment.
  • the schemes elsewhere herein do not show the use of this modification with lysine.
  • the resulting mixture was treated with 4-dimethylamino- pyridine (92 mg, 0.75 mmol, 0.1 equiv.), followed by N,N'- diisopropylcarbodiimide (4.73 g, 37.5 mmol, 5 equiv.), and the reaction mixture was shaken at ambient temperature. After 6 hours, the solvent was removed by filtration, and the beads were washed successively with 5 x 150 mL DMF, and 5 x 150 mL methylene chloride. A small portion of the resin was checked by the Kaiser test for disappearance of free NH2, and found to be negative.
  • the resin was treated with a 30% solution of piperidine in DMF (100 mL), and shaken at 25 °C for 1 hr.
  • the resin was filtered and washed successively with 5 x 150 mL DMF and 5 x 150 mL methylene chloride A small portion of the resin was checked with the Kaiser test to assure removal of the Fmoc groups, and found to be positive.
  • the solvent was removed by filtration, and the resin was washed successively with 5 x 150 mL DMF and 5 x 150 mL CH2C12 to afford the acetate protected resin. A small aliquot of the resin was checked for disappearance of free NH2 with the Kaiser test, and found to be negative.
  • the acetate protected resin from above was treated with a solution of 10% hydrazine hydrate in methanol (100 mL), and shaken at ambient temperature. After 6 hr., the solvent was removed by filtration, and the resin was washed successively with 5 x 150 mL MeOH and then re-treated with 10% hydrazine hydrate in MeOH (100 mL) and shaken at 25 C for 16 hr. The solvent was removed by filtration, and the resin was washed successively with 5 xl50 mL DMF and 5 x 150 mL CH2CI2 to afford the hydroxy resin A.
  • N-Fmoc-L-proline p-alkoxybenzyl resin, 1 (Bachem) (0.34 mmole/g, 2.0 g, 0.68 mmole) was suspended in 30 mL DMF, then filtered. The resin was then shaken with 50% piperidine/DMF for 2 hr. then filtered and washed with DMF (5 x 30 mL) and methylene chloride (10 x 30 mL). The resin was suspended in 20 mL methylene chloride, and 2 mL (14 mmole) triethylamine was added, followed by 1.0 g (5.5 mmole, 8 equiv.) 2-azidobenzoyl chloride.
  • the mixture was shaken at 25°C for 3 hr. and then the resin was washed with methylene chloride (10 x 30 mL) followed by toluene (10 x 30 mL).
  • the resin, 2 was suspended in 20 mL toluene and 0.3 g (1.14 mmole, 1.7 equiv.) triphenylphosphine was added and the mixture was shaken until the triphenylphosphine had dissolved.
  • the mixture was shaken and heated to 80°C for 3 hr. then cooled and washed with methylene chloride (10 x 30 mL).
  • the pale brown resin, 3, was dried under vacuum.
  • the resin, 3 (2.0 g, 0.68 mmole), prepared as described above, was suspended in 20 mL methylene chloride and 20 mL trifluoroacetic acid was added. The resin was shaken at 25 °C for 30 min then filtered and washed with methylene chloride (2 x 20 mL). The filtrate and washings were collected and combined, then evaporated to give the crude product.
  • the benzodiazepine was purified by flash chromatography, eluting with 60% ethyl acetate/hexane to give the product, 4, as a white solid.
  • N-Fmoc-c5-4-benzoyloxy-L-proline p-alkoxybenzyl resin, 5, (400 mg) was suspended in 10 mL DMF, then filtered. The resin was then shaken with 50% piperidine/DMF, 10 mL, for 2 hr. then filtered and washed with DMF (5 x 10 mL) and methylene chloride (10 x 10 mL). The resin was suspended in 10 mL methylene chloride, 0.4 mL ( ⁇ 3 mmole) triethylamine was added, followed by 0.2 g (1.1 mmole) 2-azido-benzoyl chloride. The mixture was shaken at 25°C for 12 hr.
  • N-Fmoc-L-proline p-alkoxybenzyl resin, 1 (0.34 mmole/g, 5.0 g, 1.8 mmole) was suspended in 50 mL DMF, then filtered. The resin was then shaken with 50% piperidine/DMF for 2 hr. then filtered and washed with DMF (5 x 50 mL) and methylene chloride (10 x 50 mL). The resin was suspended in 50 mL methylene chloride, 3 mL (21 mmole) triethylamine was added, followed by 0.75 g (3 mmole, 1.7 equiv.) 2-azido-4,5-dimethoxybenzoyl chloride as a solid.
  • the mixture was shaken at 25 °C for 12 hr. and then the resin was washed with methylene chloride (10 x 50 mL), followed by toluene (10 x 50 mL).
  • the resin, 9, was suspended in 50 mL toluene and 1.26 g (4.8 mmole 2.6 equiv.) triphenylphosphine was added and the mixture was shaken until the triphenylphosphine had dissolved.
  • the mixture was shaken and heated to 80°C for 2 hr. then cooled and washed with toluene (10 x 50 mL), alternately with methanol and methylene chloride (5 x 50 mL each) and finally methylene chloride (5 x 50 mL).
  • the pale brown resin, 1 was dried under vacuum.
  • N-Fmoc-N-methyl-L- phenylalanine, 3.0 g (7.5 mmole, 3 equiv.), DMAP, 1.0 g (0.82 mmole, 0.3 equiv.), and DIC 1.74 mL (1.26 g, 10 mmole, 4 equiv.) were added and the mixture was agitated for 2 hr.
  • the resin was filtered and washed with methylene chloride, (10 x 30 mL), then dried.
  • the mixture was shaken at 25 C for 1 hr and then the resin was washed with methylene chloride (10 x 30 mL) followed by toluene (10 x 30 mL).
  • the resin, 14, was suspended in 20 mL toluene and 0.52 g (2.0 mmole) triphenylphosphine was added and the mixture was shaken until the triphenylphosphine had dissolved.
  • the mixture was shaken and heated to 9 C for 3 hr then cooled and washed with toluene (5 x 20 mL) and methylene chloride (10 x 20 mL) to give the resin linked 1,4- benzodiazepine-5-one, 15.
  • the resin, 15, was suspended in 10 mL methylene chloride and 10 mL trifluoroacetic acid was added. The resin was shaken at 25 ° C for 2 hr, then filtered and washed with methylene chloride (2 x 20 mL). The filtrate and washings were collected and combined, then evaporated to give the crude product which was purified by flash chromatography eluting with 50% ethyl acetate/hexane to give the product, 16.
  • Rhodium (II) trifluoroacetate dimer 2 mL of 1 mg/mL in methylene chloride, was added to each vessel in turn with - 30 sec agitation of the vessels after each addition.
  • the resin batches, tag precursor and catalyst were agitated for 12 hr, then filtered and washed with 5 x 40 mL methylene chloride.
  • the 62 resin batches were encoded with six tags as follows.
  • the resin batches were suspended in 30 mL methylene chloride. Aliquots, 2 mL of 37 mg/mL (74 mg tag precursor/vessel -8.7 % by mass of resin), of C6CI5 tag precursor solution in methylene chloride were added to the appropriate vessels from 3 to 62 and the vessels were shaken for 2 min. A 3 mL aliquot of 37 mg/mL C6CI5 tag precursor solution was added to vessel 1 (111 mg tag precursor in vessel 1, 6.3% by mass of resin).
  • a collection of 51 319 l,4-benzodiazepine-2,5-diones was prepared as follows. Resin batches 3C-62C were combined and mixed thoroughly in a seperatory funnel, then divided as a slurry in methylene chloride into nineteen equal portions (-2.7 g, 1.4 mmole) in 100 mL synthesis vessels. The resin was suspended in 30 mL methylene chloride and diisopropylethylamine, 2.5 mL (1.8 g, 14 mmole, 10 equiv), was added followed by 5 mmole of the appropriate o- azidobenzoyl chloride (Reagent Set 3).
  • Tributylphosphine 1.8 mL (1.45 g, 7.2 mmole, 5 equiv), was added to each flask and the mixtures were heated to 140- 150°C for 6 hr, then cooled, filtered, and washed with 2 x 30 mL toluene and 5 x 30 mL methylene chloride to give the resin linked benzodiazepines, E.
  • the product 1 ,4-benzodiazepine-2,5-diones, F were cleaved from the resin support by suspending the resin, 20 beads, in 100 ⁇ L of 70 % TFA/water for 4 hours and filtering the solution.
  • a second collection of 1 170 l,4-benzodiazepine-2,5-diones was prepared as follows. Resin batches 1C and 2C were combined and mixed thoroughly in a seperatory funnel. The resin was dried in vacuo and divided into thirteen equal portions (-0.27 g, 0.14 mmole) then placed in 20 mL synthesis vessels. The resin was suspended in 10 mL methylene chloride and diisopropylethylamine, 0.25 mL (0.18 g, 1.4 mmole, 10 equiv), was added followed by 0.5 mmole of thirteen o- azidobenzoyl chlorides.
  • Tributylphosphine 0.14 mL (0.11 g, 0.55 mmole, 4 equiv), was added to each flask and the mixtures were heated to 140-150°C for 6 hr, then cooled, filtered, and washed with 2 x 10 mL toluene and 5 x 10 mL methylene chloride to give the resin batches E, from which the product l,4-benzodiazepine-2,5-diones, F, may be cleaved as described above.
  • the GC analysis is performed with a Hewlett Packard 5890 plus gas chromatograph. On column injection into a 5 m, 0.32 mm retention gap connected to a 25 m, 0.2 mm crosslinked 5% phenylmethyl silicone column is used.
  • the temperature and pressure programs for the analysis are 200-320°C, 15°C/min, then 320°C for 10 min and 20-40 psi at 2 psi/min, then 40 psi for 10 min.
  • the EC detector is maintained at 400°C and the auxiliary gas is set at 35 psi.
  • the identity of the library compound attached to the bead is ascertained based on the reagents utilized in the synthesis of such compound, which are readily determined from the binary codes associated, respectively, with each of the identifiers for such reagents, as characterized through the above procedure.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un procédé nouveau permettant de synthétiser une banque combinatoire de 1,4-benzodiazépine-2,5-diones sur des supports solides par l'intermédiaire de la fermeture d'un cycle d'aza-Wittig. Les composés en question peuvent, le cas échéant, être encodés avec des étiquettes. L'invention concerne également l'utilisation de cette banque dans des analyses pour découvrir des composés actifs dans le domaine biologique et, en option, en séparer les 1,4-benzodiazépine-2,5-diones.
EP96923532A 1995-06-29 1996-06-28 Banque combinatoire de 1,4-benzodiazepine-2,5-diones Withdrawn EP0850238A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65795P 1995-06-29 1995-06-29
US657P 1995-06-29
PCT/US1996/011070 WO1997001560A1 (fr) 1995-06-29 1996-06-28 Banque combinatoire de 1,4-benzodiazepine-2,5-diones

Publications (2)

Publication Number Publication Date
EP0850238A1 true EP0850238A1 (fr) 1998-07-01
EP0850238A4 EP0850238A4 (fr) 1998-10-07

Family

ID=21692463

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96923532A Withdrawn EP0850238A4 (fr) 1995-06-29 1996-06-28 Banque combinatoire de 1,4-benzodiazepine-2,5-diones

Country Status (5)

Country Link
EP (1) EP0850238A4 (fr)
JP (1) JPH11508563A (fr)
AU (1) AU6402096A (fr)
CA (1) CA2225914A1 (fr)
WO (1) WO1997001560A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5191404A (en) * 1989-12-20 1993-03-02 Digital Equipment Corporation High density memory array packaging

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO2000012508A2 (fr) 1998-08-27 2000-03-09 Spirogen Limited Composes
GB9818732D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collection of compounds
GB9818730D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
US6939712B1 (en) 1998-12-29 2005-09-06 Impedagen, Llc Muting gene activity using a transgenic nucleic acid
US6909006B1 (en) 1999-08-27 2005-06-21 Spirogen Limited Cyclopropylindole derivatives
US20030215871A1 (en) * 2002-05-01 2003-11-20 Pharmacopeia, Inc. Chemically inert molecular tags
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
US8088759B2 (en) * 2005-11-01 2012-01-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
CA2915237C (fr) 2009-11-17 2017-10-10 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones et composes apparentes presentant des proprietes therapeutiques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008051A1 (fr) * 1992-10-01 1994-04-14 The Trustees Of Columbia University In The City Of New York Banques chimiques combinatoires complexes codees avec des etiquettes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173912A (en) * 1961-10-02 1965-03-16 Olin Mathieson Benzodiazepines
US3860600A (en) * 1972-07-10 1975-01-14 Sterling Drug Inc Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008051A1 (fr) * 1992-10-01 1994-04-14 The Trustees Of Columbia University In The City Of New York Banques chimiques combinatoires complexes codees avec des etiquettes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B BUNIN ET AL: "A general and expedient method for the solid-phase synthesis of 1,4-benzodiazepine derivatives" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 114, no. 27, 1992, pages 10997-10998, XP002072683 *
BUNIN B A ET AL: "Synthesis and evaluation of 1,4-benzodiazepine libraries" METHODS ENZYMOL. (MENZAU,00766879);96; VOL.267 (COMBINATORIAL CHEMISTRY); PP.448-465, UNIV. CALIFORNIA;DEP. CHEM.; BERKELEY; 94720; CA; USA (US), XP002072681 *
S EGUCHI ET AL: "Facile synthesis of 1,4-benzodiazepin-5-ones via inramolecular aza-wittig reaction" SYNLETT, 1992, pages 295-296, XP002072682 *
See also references of WO9701560A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5191404A (en) * 1989-12-20 1993-03-02 Digital Equipment Corporation High density memory array packaging

Also Published As

Publication number Publication date
JPH11508563A (ja) 1999-07-27
EP0850238A4 (fr) 1998-10-07
AU6402096A (en) 1997-01-30
WO1997001560A1 (fr) 1997-01-16
CA2225914A1 (fr) 1997-01-16

Similar Documents

Publication Publication Date Title
US5962337A (en) Combinatorial 1,4-benzodiazepin-2,5-dione library
US6265228B1 (en) Process for preparing combinatorial amide alcohol libraries
US5948696A (en) Combinatorial biaryl amino acid amide libraries
US5968736A (en) Methods for recording the reaction history of a solid support
US6001579A (en) Supports and combinatorial chemical libraries thereof encoded by non-sequencable tags
AU686579B2 (en) Complex combinatorial chemical libraries encoded with tags
EP0879219B1 (fr) Marqueurs attaches destines a etre utilises dans la synthese chimique combinatoire
EP0850238A1 (fr) Banque combinatoire de 1,4-benzodiazepine-2,5-diones
US5972719A (en) Combinatorial hydroxy-amino acid amide libraries
EP0734398B1 (fr) Composes et procedes
US20030119059A1 (en) Complex combinatorial chemical libraries encoded with tags
WO1998011036A9 (fr) Marqueurs attaches destines a etre utilises dans la synthese chimique combinatoire
US6503759B1 (en) Complex combinatorial chemical libraries encoded with tags
WO2005040073A2 (fr) Synthese en phase solide de 3-aryl-2-carboxamido-indolyl
US6228986B1 (en) Solid-phase synthesis of novel 14-membered macroycles for high throughput screening
CA2226691C (fr) Bibliotheque combinatoire de 1,4-benzodiazepine-2,5-dione
WO1998015532A1 (fr) Synthese en phase solide de composes heterocycliques
AU705844B2 (en) Combinatorial 1,4-benzodiazepin-2, 5-dione library
US5773512A (en) Compounds and methods
CA2389953A1 (fr) Nouveaux reactifs polymeres fonctionnalises
US5783698A (en) Chemical synthesis of 1,3-disubstituted quinazolinediones
KR100901316B1 (ko) 신규한 테트라하이드로-1,4-벤조디아제핀-5-온 유도체 및그의 고체상 제조방법
WO2005040111A2 (fr) Bibliotheque combinatoire d'acides 3-aryl-1h-indole-2-carboxyliques
WO2009037642A1 (fr) Echafaudages hétérocycliques utiles pour la préparation de bibliothèques combinatoires, bibliothèques et leurs procédés de préparation
Sandulenko et al. Development of Privileged Groebke-Blackburn-Type 4-(3-aminoimidazo [1, 2-a] pyridin-2-yl) benzoic Acid Core into a Combinatorial Library on Solid Phase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980820

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010426

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010907